Comparing the current results to its competitors, Orchard Therapeutics Plc reported Revenue increase in the 3 quarter 2023 by 9.09 % year on year. The sales growth was above Orchard Therapeutics Plc's competitors' average revenue growth of 2.03 %, achieved in the same quarter.
With revenue growth of 9.09 % within Overall company, Orchard Therapeutics Plc achieved improvement in market share, within Overall company to approximately 0.07 %. << More on ORTX Market Share.
*Market share is calculated based on total revenue.
May 7, 2024
These presentations underpinned the tremendous scope and variety of HSC gene therapy a pioneering and innovative treatment that is shaking the foundations of our perspective on the management of challenging ...
May 3, 2024
In a testament to his monumental impact and revolutionary advancements in the global health sector, Dr. Bobby Gaspar, co-founder and Chief Executive Officer (CEO) of Orchard Therapeutics, has been named to the inaugural TIME100 Health list for 2024. The list, compiled annually, recognizes the ingenuity, innovation, and tangible influence of the most revolutionary individuals across the healthcare spectrum.Gaspar, now steering the helm of Orchard Therapeutics after it was recently acquired by Kyowa Kirin, is recognized globally for his tireless and revolutionary work in gene therapies. Under Gaspar s leadership, Orchard has steadfastly worked towards accelerating the advent of new gene therapies, with the pot...
February 5, 2024
Orchard Therapeutics, a leading global gene therapy company, has recently announced the randomization of the first patient in a registrational trial of its experimental gene therapy OTL-203 as a treatment for Mucopolysacianosis Type I (MPS-I) Hurler Syndrome. The therapy, which is based on an innovative ex vivo autologous hematopoietic stem cell gene therapy approach, aims to replace faulty genetics at the cellular level to potentially provide a curative solution to patients with genetic conditions such as MPS-I.MPS-I is a rare, fatal genetic disorder that causes developmental anomalies and systemic organ failure. It is caused by mutations in the gene for an enzyme called alpha-L-iduronidase (IDUA), leading...
February 2, 2024
The 20th Annual WORLDSymposium witnessed several enlightening presentations and posters by Orchard Therapeutics, showcasing groundbreaking advancements in hematopoietic stem cell (HSC) gene therapy and newborn screening. These cutting-edge approaches hold immense promise in addressing severe neurometabolic diseases, heralding a potential breakthrough in the field of pharmaceutical sciences.:This article aims to ly outline the key findings and transformative potential of HSC gene therapy and newborn screening as presented by Orchard Therapeutics at the 20th Annual WORLDSymposium. By interpreting the facts presented in these presentations and posters, we seek to provide a clear overview of the advancements mad...
January 25, 2024
Orchard Therapeutics, a leading player in the global gene therapy industry, announced a crucial agreement with the Beneluxa Initiative on Pharmaceutical Policy, also known as Beneluxa, on January 25, 2024. With this agreement, individuals residing in certain member countries of Beneluxa will now have access to a reimbursed application of Libmeldy, a ground-breaking hematopoietic stem cell (HSC) gene therapy.Libmeldy, also known in technical terms as atidarsagene autotemcel, was initially approved to be used as a treatment method for early-onset metachromatic leukodystrophy (MLD). MLD is a rare genetic disorder that primarily affects the nervous system, causing progressive deterioration over time. Libmeldy, d...
In a promising development for the rare genetic disorder known as mucopolysaccharidosis type I-Hurler syndrome (MPS-IH), Orchard Therapeutics has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) for its innovative therapy, OTL-203. This breakthrough offers hope to patients and their families, as it will enable expedited development and potential approval of a much-needed treatment. However, recent financial results have shown a slower revenue growth rate for Orchard Therapeutics compared to its competitors. In this article, we will delve into the significance of the Fast Track Designation for OTL-203 and explore the potential reasons behind the company s comparativ...
Genenta Science S.p.A. operates on a business model focused on the development of immuno-gene therapies for the treatment of cancer. They aim to leverage their proprietary technology to genetically modify autologous hematopoietic stem cells and engineer them to express immunomodulatory protein IL-12. These modified cells are then reinfused into patients to stimulate an immune response against tumors, potentially offering a novel and personalized approach to cancer treatment.
Gilead Sciences Incs business model centers on researching, developing, and marketing innovative medicines, primarily targeting antiviral therapies. They focus on addressing unmet medical needs to enhance patient health globally.
4D Molecular Therapeutics Inc operates with a business model focused on developing innovative gene therapy products to address serious genetic diseases. The company utilizes its proprietary technology platform to design and optimize viral vectors for targeted gene delivery. With a strong commitment to research and development, 4D Molecular Therapeutics collaborates with partners in academia, industry, and patient organizations to advance transformative treatments for patients in need.
Eiger Biopharmaceuticals Inc is a biotechnology company focused on developing and commercializing innovative therapies for serious rare and ultra-rare diseases.
Sources:
Orchard Therapeutics Plc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Orchard Therapeutics Plc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
